HT1197 Orthotopic Mouse Model Service for Bladder Cancer

The HT1197 orthotopic mouse model captures the aggressive, poorly differentiated biology of a human grade IV urothelial carcinoma within its native bladder microenvironment, leveraging a extensively molecularly characterized cell line with p53 mutation, 9p21 homozygous deletion, and documented multidrug-resistance potential. Alfa Cytology delivers this human xenograft platform with authenticated cell-line provenance, optimized intramural surgical implantation, and integrated CA19.9-targeting analytics, ensuring reproducible high-grade tumor engraftment and pharmacodynamic readouts aligned with aggressive human bladder cancer biology.

Overview of HT1197 Orthotopic Mouse Model for Bladder Cancer

HT1197 is a human bladder transitional cell carcinoma line originally established in 1977 by Rasheed and colleagues from a grade IV (G4) tumor excised from the urinary bladder of a 44-year-old Caucasian male who had not received prior chemotherapy or radiation. The line is among the most extensively molecularly profiled human bladder cancer cell lines, having been characterized across all five major genomic panels—CCLE, UBC-40, GDSC, TCPA, and BLA-40—making it a cornerstone reference for urothelial carcinoma research. Genetically, HT1197 harbors a mutant TP53 allele, a large homozygous deletion of the 9p21 locus that simultaneously inactivates CDKN2A, CDKN2B, and MTAP, and a TERT promoter mutation that drives constitutive telomerase activity. It also carries an activating BRAF mutation and expresses high levels of CA19.9, a tumor-associated glycan antigen that has been exploited for immuno-PET imaging in preclinical xenograft settings. Phenotypically, HT1197 exhibits epithelial-like morphology with pronounced proliferative activity, grows robustly in soft agar, produces fibrinolytic activity, and expresses CD44 splice variants linked to phenotypic atypia. When implanted orthotopically into the bladder wall of athymic nude mice, HT1197 cells generate rapidly expanding, poorly differentiated tumors that recapitulate the aggressive, high-grade nature of human muscle-invasive bladder cancer.

Fig 1. Technical refinement of the mouse orthotopic bladder cancer model. (Naito, Tomoharu, et al., 2020)

The model's basal-like molecular classification—supported by p53 dysfunction, CDKN2A loss, and absence of luminal differentiation markers—renders it particularly suited for evaluating DNA-damage response modulators, CDK4/6 inhibitors, MTAP-deletion-targeted strategies (such as PRMT5 inhibitors), and cytotoxic agents that bypass multidrug-resistance efflux pathways. Notably, HT1197 xenografts have demonstrated robust sensitivity to the targeted cytotoxic LHRH analog AN-152 while exhibiting acquired resistance to conventional doxorubicin through active drug-efflux mechanisms, providing a clinically relevant backdrop for testing next-generation targeted therapeutics and resistance-reversal strategies in an anatomically faithful, immunodeficient preclinical setting.

Cell Line Information: HT1197

HT1197 is a deeply characterized human urothelial carcinoma line with well-documented genetic driver alterations, aggressive in vitro behavior, and proven tumorigenicity in immunodeficient rodents. The table below summarizes its origin, molecular profile, and technical parameters for preclinical study design.

Our Services

Alfa Cytology constructs and manages HT1197 orthotopic cohorts with authenticated, STR-verified cell stocks, calibrated surgical implantation protocols, and comprehensive endpoint analytics spanning CA19.9 immunohistochemistry, CDK-pathway profiling, and multidrug-resistance efflux assays. Our team tailors every inoculum density, preconditioning regimen, and tissue-harvesting schedule to your compound mechanism—whether you are interrogating PRMT5 inhibition in an MTAP-null context, validating CA19.9-targeted delivery vectors, or reversing doxorubicin resistance—ensuring datasets that withstand regulatory scrutiny and advance your pipeline with confidence.

Workflow of HT1197 Orthotopic Mouse Model Construction

Construction of the HT1197 orthotopic model demands precise surgical delivery into the bladder wall to exploit the line's robust anchorage-independent growth and fibrinolytic activity, while minimizing perioperative morbidity in immunodeficient hosts. The workflow below reflects optimized methodologies validated for high-grade human bladder cancer preclinical research.

1. Cell Preparation and Authentication: HT1197 cells are expanded in complete EMEM EBSS medium and harvested during logarithmic growth phase. Short tandem repeat (STR) profiling is performed to confirm identity against the reference profile (Amelogenin: X,Y; CSF1PO: 11,12; D5S818: 12; D7S820: 11,12; D13S317: 11,12; D16S539: 12,13; TH01: 6,9.3; TPOX: 11,12; vWA: 16,18). Viability is assessed by trypan blue exclusion, with only suspensions exceeding 90% viability accepted. Cells are washed twice in PBS, counted, and resuspended at 1×10⁸ cells/mL in serum-free medium or PBS on ice.
2. Animal Preparation and Anesthesia: Female athymic nude mice (nu/nu), 6–8 weeks old, are acclimatized for a minimum of one week under SPF barrier conditions. On the procedure day, general anesthesia is induced via isoflurane inhalation (3% for induction, 1.8% maintenance at 2 L/min oxygen) or intraperitoneal sodium pentobarbital (60 mg/kg). Depth of anesthesia is confirmed by absence of the toe-pinch reflex. Buprenorphine and meloxicam are administered subcutaneously for perioperative analgesia. Mice are placed on a heated surgical pad in supine position, and the lower abdominal wall is disinfected with chlorhexidine.
3. Surgical Exposure of the Bladder: A low transverse laparotomy is performed to exteriorize the urinary bladder. The bladder is gently emptied by manual compression and stabilized with moistened gauze. A 25-gauge needle is used to create a small puncture in the ventral bladder wall, or a 30-gauge Hamilton syringe is inserted directly into the detrusor muscle layer for intramural delivery.
4. Intramural HT1197 Injection: The prepared cell suspension (50–100 µL containing 5×10⁵ to 1×10⁶ cells) is injected slowly into the bladder wall at a controlled rate to minimize back-leakage. The needle is held in place for 30 seconds after injection to allow fibrin deposition and prevent reflux. The bladder is then returned to the abdominal cavity, and the laparotomy incision is closed in two layers with absorbable suture.
5. Postoperative Recovery and Health Surveillance: Mice are transferred to a warmed recovery chamber and monitored until fully mobile. Body weight, hydration status, hematuria, and general behavior are recorded daily for the first 72 hours. Analgesia is maintained according to institutional IACUC guidelines. Mice exhibiting >15% body-weight loss, signs of urinary obstruction, wound dehiscence, or persistent hematuria are flagged for veterinary assessment.
6. Longitudinal Tumor Monitoring: Tumor establishment and growth are monitored via periodic small-animal ultrasound or micro-CT imaging, beginning at day 7 post-inoculation and performed twice weekly thereafter. Tumor volume is calculated using the ellipsoid formula (length × width² × 0.5). Body weight and hematuria scores are recorded every two days. Where CA19.9-targeting agents are under evaluation, serial serum CA19.9 ELISA may be performed to assess antigen shedding dynamics.
7. Terminal Necropsy and Multi-Modal Endpoint Analysis: At humane endpoint or protocol-defined timepoints (typically 3–4 weeks), mice are euthanized. The bladder is excised, weighed, opened longitudinally, and photographed. Tumor differentiation status is confirmed by hematoxylin and eosin (H&E) staining. Immunohistochemistry is performed for CA19.9, Ki-67, p53, CD44, and CD31. Tissues are partitioned for snap-frozen molecular extraction (RNA/DNA/protein), formalin-fixed paraffin-embedded (FFPE) archiving, and—where applicable—multidrug-resistance efflux assays and PRMT5 activity quantification in MTAP-null tumor lysates.

Fig 2. HT1197 Orthotopic Mouse Model construction workflow.

Case Study-HT1197 Orthotopic Mouse Model Development

In a preclinical program designed to evaluate a novel MTAP-deletion-targeted PRMT5 inhibitor in combination with a CA19.9-directed antibody-drug conjugate, Alfa Cytology established an orthotopic HT1197 cohort to leverage the line's endogenous 9p21 homozygous deletion and high CA19.9 surface expression. Following STR-authenticated cell preparation and validated intramural injection, all study animals developed palpable bladder tumors within the anticipated two-week window. The experimental architecture incorporated a vehicle control arm, a PRMT5 inhibitor monotherapy arm, a CA19.9-ADC monotherapy arm, and a combination arm. Terminal analyses revealed treatment-dependent reductions in tumor wet weight and Ki-67 proliferation indices in the combination group, while immunohistochemistry demonstrated preserved CA19.9 membrane staining and diminished PRMT5 substrate symmetric dimethylarginine (SDMA) levels in MTAP-null tumor lysates. These preclinical datasets provided the sponsor with pharmacodynamic evidence supporting further combination-dose optimization and biomarker strategy refinement for subsequent IND-enabling studies.

Why Choose Alfa Cytology?

Selecting Alfa Cytology for your HT1197 orthotopic study provides access to a preclinical infrastructure where deeply characterized human tumor biology, surgical precision, and mechanism-aligned endpoint analytics converge to accelerate therapeutic development in high-grade bladder cancer.

• STR-authenticated HT1197 cells with documented TP53 mutation, 9p21 homozygous deletion (CDKN2A/CDKN2B/MTAP), TERT promoter mutation, and BRAF alteration ensure molecular fidelity to aggressive human MIBC.
• Optimized intramural surgical implantation achieves reproducible tumor engraftment in athymic nude mice, leveraging the line's inherent soft-agar growth and fibrinolytic activity for robust anchorage-independent tumor establishment.
• The model's high CA19.9 surface expression enables preclinical validation of CA19.9-targeted immuno-PET constructs, antibody-drug conjugates, and carbohydrate-antigen-directed delivery systems.
• MTAP-null status provides a genetically defined backdrop for evaluating PRMT5 inhibitors, MAT2A-targeted strategies, and synthetic-lethal approaches in a 9p21-deleted urothelial carcinoma context.
• Documented multidrug-resistance efflux mechanisms and differential sensitivity to targeted cytotoxic analogs (e.g., AN-152 vs. DOX) support mechanistic studies of resistance reversal and next-generation cytotoxic design.
• All studies are conducted within SPF barrier facilities under IACUC-approved protocols, with comprehensive necropsy documentation, CA19.9/Ki-67/p53 immunohistochemistry packages, and GLP-compatible data deliverables available.

Contact Us

If your bladder cancer discovery program requires a deeply characterized, high-grade human orthotopic model with defined 9p21 deletion, CA19.9 expression, and proven multidrug-resistance biology, reach out to Alfa Cytology to discuss how our HT1197 platform can advance your therapeutic candidates. Our scientific team will design a customized study architecture, select optimal endpoint analytics aligned with your compound mechanism, and provide a comprehensive project proposal. Contact us today to translate aggressive urothelial carcinoma biology into actionable, data-driven translational insights.

For research use only. Not intended for any clinical use.